Intellectual Property

MDI owns a broad patent covering key aspects of the technology underlying its MRSA (methicillin-resistant Staphylococcus aureus) detection methods and its Detect-Ready® kit, as well as an extensive portfolio of additional patent applications around its Detect-Ready molecular diagnostic testing platform for infectious disease detection. The recently issued patent titled “Methods, Compositions and Kits for Detection and Analysis of…

Technology

MDI’s Detect-Ready® molecular diagnostic tests represent a major breakthrough in real-time (rt) PCR testing. rt-PCR testing offers accurate detection of pathogens at extremely low target concentrations in samples, but more widespread use has been restricted by the many practical problems it traditionally entailed, including the need for cold storage and highly skilled technicians to prepare…